Balancing Innovation and Drug Pricing in Global Cancer Care

Mark Socinski, MD, Gilberto Lopes, MD, Afsaneh Barzi, MD, PhD, and Jack West, MD, discuss the balance of using innovative cancer therapies with disruptive drug prices to make the therapies more widely available.

EP. 1: Definition of Financial Toxicity

August 9th 2021

Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.

EP. 2: Role of Financial Toxicity on Treatment Decisions

August 9th 2021

Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.

EP. 3: Personalized Therapies Based on Innovation and Affordability

August 16th 2021

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

EP. 4: Impact of Payers on the Costs of Drugs

August 16th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

EP. 5: EGFR-Targeted TKIs in NSCLC and Cost

August 23rd 2021

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

EP. 6: Review of AENEAS Trial and Similar Agents

August 23rd 2021

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

EP. 7: Place for EGFR Agents and Comparison of Costs

August 30th 2021

A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.

EP. 8: Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers

August 30th 2021

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

EP. 9: Pharmacoeconomic Considerations for Immunotherapy

September 7th 2021

Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.

EP. 10: Significance of PD-L1/PD-1 Testing in NSCLC

September 7th 2021

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

EP. 11: Review of GEMSTONE-301 and -302 Data

September 13th 2021

Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.

EP. 12: Mitigating Strategies Appropriate for EGFR Therapy and Financial Toxicity

September 13th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.

EP. 13: Innovation of Therapies vs Disruptive Pricing

September 20th 2021

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

EP. 14: Final Thoughts on Effective Therapy and Financial Toxicity

September 20th 2021

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.